山东大学耳鼻喉眼学报 ›› 2017, Vol. 31 ›› Issue (6): 5-8.doi: 10.6040/j.issn.1673-3770.1.2017.039
• 甲状腺癌的规范化诊断与治疗·专题笔谈 • 上一篇 下一篇
邱杰1,孙莎莎2,孙彦1
QIU Jie1, SUN Shasha2, SUN Yan1
摘要: TNM分期系统是目前国际上最为通用的肿瘤分期系统,确定T、N、M后就可以得出相应的总的分期,即Ⅰ期、Ⅱ期、Ⅲ期、Ⅳ期。美国癌症联合委员会(AJCC)制定的肿瘤TNM分期标准已被广泛认可和应用。近期AJCC发布的第8版肿瘤TNM分期将于2018年1月1日正式在全球实施。对AJCC第8版中甲状腺癌TNM分期标准的内容及其相对于第7版的改动进行解读。
中图分类号:
[1] 刘荫华, 姚宏伟, 周斌,等. 美国肿瘤联合会结直肠癌分期系统(第8版)更新解读[J].中国实用外科杂志, 2017, 37(1):6-9. LIU Yinhua, YAO Hongwei, ZHOU Bin, et al. Updates and interpretations of AJCC cancer staging manual 8th edition for colorectal carcinoma[J].Chin J Prac Surg, 2017, 37(1):6-9. [2] 孙彦, 王琪. 2002年AJCC甲状腺癌分期方案[J].国际耳鼻咽喉头颈外科杂志,2004, 28(6):385-386. [3] 孙威, 贺亮, 张浩. 美国癌症联合委员会甲状腺癌分期系统(第8版)更新解读[J].中国实用外科杂志, 2017, 37(3):255-258. SUN Wei, HE Liang, ZHANG Hao. Interpretations on the updates of American Joint Committee on cancer staging system(8th edition)for thyroid cancer[J]. Chin J Prac Surg, 2017, 37(3):255-258. [4] Kim M, Kim YN, Kim WG, et al. Optimal cutoff age in the TNM staging system of differentiated thyroid cancer: is 55 years better than 45 years?[J].Clin Endocrinol, 2017, 86(3):438-443. [5] Tuttle RM, Haugen B, Perrier ND. The updated AJCC/TNM staging system for differentiated and anaplastic thyroid cancer(8th edition): what changed and why?[J]. Thyroid, 2017, 27(6):751-756. [6] Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6):1471-1474. [7] Edge SB. AJCC cancer staging manual[J]. Jama, 2010, 304(15):1726-1727. [8] Beahrs OH, Myers MH. American Joint Committee on cancer manual for staging of cancer[M]. 2nd ed. Philadelphia: JB Lippincott, 1983. [9] Nixon IJ, Wang LY, Migliacci JC, et al. An international multi-institutional validation of age 55 years as a cutoff for risk stratification in the AJCC/UICC staging system for well-differentiated thyroid cancer.[J]. Thyroid, 2016, 26(3):373-380. [10] Kim M, Kim WG, Oh HS, et al. Comparison of the 7th and 8th editions of the AJCC/UICC TNM staging system for differentiated thyroid cancer[J]. Thyroid, 2017, 27(9):1149. [11] Kim TH, Kim YN, Kim HI, et al. Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma[J]. Oral Oncol, 2017, 71:81-86. [12] Beahrs O, Carr DT, Rubin P. American Joint Committee for cancer staging and end results reporting[M]. Manual for Staging of Cancer. Philadelphia, PA: J B Lippincott Co., 1977. [13] Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6):1471-1474. [14] Wells SA Jr, Asa SL, Dralle H, et al. Revised American thyroid association guidelines for the management of medullary thyroid carcinoma[J]. Thyroid, 2015, 25(6):567-610. [15] Jin LX, Moley JF. Surgery for lymph node metastases of medullary thyroid carcinoma: A review[J]. Cancer, 2016, 122(3):358-366. [16] Boostrom SY, Grant CS, Thompson GB, et al. Need for a revised staging consensus in medullary thyroid carcinoma.[J]. Arch Surg, 2009, 144(7):663-669. [17] Tuttle RM, Ganly I. Risk stratification in medullary thyroid cancer: moving beyond static anatomic staging[J]. Oral Oncol, 2013, 49(7):695-701. [18] Yang JH, Lindsey SC, Camacho CP, et al. Integration of a postoperative calcitonin measurement into an anatomical staging system improves initial risk stratification in medullary thyroid cancer[J]. Clin Endocrinol, 2016, 83(6):938-942. [19] Wang W, Sun XW, Li CF, et al. Comparison of the 6th and 7th editions of the UICC TNM staging system for gastric cancer: results of a Chinese single-institution study of 1,503 patients[J]. Ann Surg Oncol, 2011, 18(4):1060-1067. [20] Kim TY, Kim WG, Kim WB, et al. Current status and future perspectives in differentiated thyroid cancer[J]. Endocrinol Metab, 2014, 29(3):217-225. |
[1] | 孙国臣,孙彦,张虹,王保为. 儿童分化型甲状腺癌的临床特征及治疗体会[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 25-28. |
[2] | 潘永杰,庞文会,孙国臣,孙彦,张虹. 乙酰肝素酶和D2-40在儿童甲状腺癌中的表达及临床意义[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 29-32. |
[3] | 普布次仁,刘吉峰,巴罗. 甲状腺癌与外周静脉血炎性相关指标[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 21-24. |
[4] | 徐书杭, 李春睿, 刘超. 儿童甲状腺癌的规范化诊治[J]. 山东大学耳鼻喉眼学报, 2017, 31(6): 12-15. |
[5] | 余济春. 分化型甲状腺癌颈淋巴结清扫术[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 10-12. |
[6] | 邱杰,孙彦. 肿瘤标志物检测在甲状腺癌临床诊治中的意义[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 28-31. |
[7] | 李莹莹综述, 宋西成审校. DNA双链断裂修复基因的单核苷酸多态性与甲状腺癌的研究进展[J]. 山东大学耳鼻喉眼学报, 2016, 30(2): 102-105. |
[8] | 赵国伟,贺青卿,庄大勇,郑鲁明,范子义,朱见,于芳,周鹏,侯蕾,姜会平. 131I治疗分化型甲状腺癌的应用价值与风险[J]. 山东大学耳鼻喉眼学报, 2013, 27(6): 16-21. |
[9] | 曹磊,贺青卿,庄大勇,郑鲁明,范子义,周鹏,朱见. 选择低位小切口行甲状腺癌选择性淋巴结清扫[J]. 山东大学耳鼻喉眼学报, 2013, 27(2): 56-59. |
[10] | 范林军1,明佳1,黄定德2,范子义1, 赵德龙3,张毅1,杨新华1,姜军1. 腔镜甲状腺近全切除序贯131I消融治疗分化型甲状腺癌[J]. 山东大学耳鼻喉眼学报, 2011, 25(5): 11-16. |
[11] | 伊海金1,张宝泉2. 甲状腺癌的外科治疗分析[J]. 山东大学耳鼻喉眼学报, 2010, 24(4): 10-12. |
[12] | 张 虎,艾 琴 . 甲状腺癌再手术15例[J]. 山东大学耳鼻喉眼学报, 2007, 21(2): 166-167 . |
|